Internal jugular vein semi-permanent catheter with self-adaptive epidermal growth factor release mechanism

Abstract

The invention discloses an internal jugular vein semi-permanent catheter with a self-adaptive epidermal growth factor release mechanism, and belongs to the technical field of medical instruments. The catheter comprises a catheter body and a multifunctional medicine release covering film arranged at the telecentric end in a covering mode, the covering film is made of biocompatible polymers, epidermal growth factors (EGF) and antibacterial agents are loaded on the covering film in a gradient mode, and a micro sensor is arranged in the covering film. The sensor is linked with an intelligent feedback system, the drug release rate can be dynamically adjusted according to local physiological conditions, and meanwhile wireless data transmission and remote monitoring are supported. The defects of an existing semi-permanent catheter in the aspects of infection prevention, healing promotion and dynamic adjustment are overcome, targeted drug release, continuous antibiosis, self-adaptive feedback and remote management are achieved, and the long-term implantation requirement is met.

Description

TECHNICAL FIELD

[0001] The present application relates to the technical field of medical devices, in particular to a jugular vein semi-permanent catheter with a self-adaptive epidermal growth factor release mechanism. BACKGROUND

[0002] In the field of medical devices, long-term intravenous catheters are widely used in hemodialysis, long-term infusion, nutritional support and other treatment scenarios as important vascular access devices in clinical practice. Among them, the jugular vein semi-permanent catheter becomes an important choice for patients who need long-term vascular access due to its relatively convenient implantation position and long-term use characteristics.

[0003] However, the existing semi-permanent catheter has significant deficiencies in clinical application, mainly in the following aspects:

[0004] (1) Limited wound healing and antibacterial function: The existing catheter usually only has basic physical access function and heparin coating anti-coagulation function in the proximal end lumen, lacks active promotion mechanism for wound healing after catheter implantation, and is difficult to achieve sustained and effective antibacterial effect. The wound healing at the implantation site is slow, which may lead to unstable catheter fixation due to poor local tissue repair; at the same time, bacteria are easy to breed at the contact part of the catheter and the blood vessel wall and on the surface of the catheter, increasing the risk of infection, and in severe cases, may cause sepsis and other complications that endanger the life of the patient.

[0005] (2) Lack of self-adaptive drug release capability: The human physiological environment is complex and dynamic, and there are differences in the local physiological conditions around the catheter of different patients or the same patient at different treatment stages. However, the existing catheter cannot independently adjust the release rate of the drug according to these local physiological changes, resulting in a mismatch between the drug release and the actual demand - possibly insufficient drug during the critical period of wound healing, or excessive drug when the risk of infection is low, which not only affects the treatment effect, but also may increase the risk of side effects due to drug abuse.

[0006] (3) High risk of complications and secondary intervention burden: Due to the above functional defects, the incidence of complications such as infection, thrombus formation and catheter dysfunction is high during the use of the existing semi-permanent catheter. In order to deal with these complications, secondary surgery or frequent clinical intervention is often required, which not only increases the pain and economic burden of the patient, but also consumes a large amount of medical resources and reduces the overall efficiency of treatment.

[0007] Therefore, in view of the deficiencies of the existing semi-permanent catheter in preventing infection, promoting wound healing, adjusting drug release and clinical management, etc., it is urgent to develop a new type of jugular vein semi-permanent catheter with better performance to solve the practical problems in clinical application. SUMMARY

[0008] The internal jugular vein semi-permanent catheter with adaptive epidermal growth factor release mechanism aims to solve the problems of the existing semi-permanent catheter in preventing infection, promoting wound healing, drug release regulation and clinical management.

[0009] To achieve the above-mentioned purpose, the internal jugular vein semi-permanent catheter with adaptive epidermal growth factor release mechanism comprises a catheter body, and a multifunctional drug release coating film is coated on the distal end of the catheter body, and an intelligent feedback system is arranged in the multifunctional drug release coating film.

[0010] Preferably, the material of the catheter body is a medical grade elastomer.

[0011] Preferably, the multifunctional drug release coating film comprises an epidermal growth factor coating film and an antibacterial agent coating film, and the epidermal growth factor EGF and the antibacterial agent are respectively coated on the distal end of the catheter body by taking a biocompatible polymer as a carrier.

[0012] The epidermal growth factor coating film is provided with epidermal growth factors with a concentration distribution from low to high along the distal end of the catheter body to the inside, and the antibacterial agent coating film is provided with antibacterial agents with a concentration distribution from low to high along the distal end of the catheter body to the inside.

[0013] Preferably, the biocompatible polymer comprises a synthetic biocompatible polymer or a natural biocompatible polymer.

[0014] The synthetic biocompatible polymer comprises polylactic acid, polyglycolic acid and polycaprolactone.

[0015] The natural biocompatible polymer comprises collagen, chitosan and cellulose.

[0016] Preferably, the intelligent feedback system comprises a micro sensor and a micro controller unit, and the micro sensor and the micro controller unit are electrically connected.

[0017] Preferably, the intelligent feedback system comprises a micro sensor and a micro controller unit, and the micro sensor and the micro controller unit are electrically connected.

[0018] Preferably, the micro sensor monitors the environmental parameters around the catheter in real time and transmits the collected environmental parameters to the micro controller unit, and the micro controller unit adjusts the dynamic control module to realize dynamic control of the release rate according to the received data.

[0019] Preferably, the micro controller unit is wirelessly connected with a monitoring terminal.

[0020] Preferably, the dynamic control module comprises a microfluidic channel and an EAP micro valve arranged at the inlet of the microfluidic channel, and the EAP micro valve is electrically connected with the micro controller unit through a micro valve connecting line.

[0021] Therefore, the internal jugular vein semi-permanent catheter with an adaptive epidermal growth factor release mechanism of the present invention has the following beneficial effects:

[0022] (1) Synergistic release of EGF and antibacterial agents, and gradient drug distribution, can simultaneously meet the needs of antibacterial and healing promotion, and improve treatment efficiency;

[0023] (2) Based on the adaptive regulation mechanism of local physiological parameters, ensure that drug release matches actual needs and improve drug safety;

[0024] (3) The sustained antibacterial effect significantly reduces the risk of catheter-related infections and reduces complications;

[0025] (4) Remote monitoring and management functions reduce the number of times patients need to travel to and from the hospital and improve the convenience of clinical operations;

[0026] (5) Both the catheter body and the covering are made of medical-grade biocompatible materials to ensure the comfort and safety of long-term implantation.

[0027] The technical solution of the present invention will be further described in detail below with reference to the accompanying drawings and embodiments. Attached Figure Description

[0028] To more clearly illustrate the technical solutions of the embodiments of the present invention, the drawings used in the description of the embodiments of the present invention will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For those skilled in the art, other drawings can be obtained based on these drawings without creative effort.

[0029] Figure 1 This is a schematic diagram of the structure of an embodiment of the present invention.

[0030] Figure label:

[0031] 1. Catheter body; 2. Multifunctional drug release coating; 3. Intelligent feedback system; 4. Dynamic control module; 5. Monitoring terminal; 201. Epidermal growth factor coating; 202. Antibacterial agent coating; 301. Microsensor; 302. Microcontroller unit; 401. Microfluidic channel; 402. EAP microvalve; 403. Microvalve connecting line. Detailed Implementation

[0032] The technical solution of the present invention will be further described below with reference to the accompanying drawings and embodiments.

[0033] To make the objectives, technical solutions, and advantages of this application clearer, more thorough, and more complete, the technical solutions of the present invention will be clearly and completely described below with reference to the accompanying drawings and embodiments. The following detailed descriptions are all illustrations of embodiments, intended to provide further detailed explanation of the present invention. Unless otherwise specified, all technical terms used in this invention have the same meaning as commonly understood by one of ordinary skill in the art to which this application pertains.

[0034] The instruments, equipment, reagents, and materials used in the examples were all obtained commercially.

[0035] Example 1

[0036] A semi-permanent internal jugular vein catheter with an adaptive epidermal growth factor release mechanism, structure as follows: Figure 1 As shown, it includes a catheter body 1, which is made of medical-grade elastomer to ensure biocompatibility and comfort during long-term implantation.

[0037] The distal end of the catheter body 1 is coated with a multifunctional drug-release coating 2, which includes an epidermal growth factor coating 201 and an antimicrobial agent coating 202. The multifunctional drug-release coating 2 is made of a biocompatible polymer and contains epidermal growth factor and antimicrobial agent.

[0038] like Figure 1 As shown, epidermal growth factor (EGF) and antibacterial agent are distributed in a gradient. Along the distal end of the catheter body 1, EGF and antibacterial agent are coated with concentrations ranging from low to high. In this embodiment, silver ions are chosen as the antibacterial agent to better balance the needs of promoting tissue healing and inhibiting bacteria.

[0039] Epidermal growth factor (EGF) and an antibacterial agent are coated onto the distal end of the catheter body 1 using biocompatible polymers as carriers. The biocompatible polymers are common synthetic polymers such as polylactic acid (PLA), polyglycolic acid (PGA), and polycaprolactone (PCL), or natural biocompatible polymers such as collagen, chitosan, and cellulose. The biocompatible polymer is selected based on the requirements of the actual preparation process, only needing to possess good bioactivity and biodegradability. In this embodiment, polylactic acid is selected as the biocompatible polymer.

[0040] To further meet the needs of using semi-permanent internal jugular vein catheters, an intelligent feedback system 3 is also incorporated, housed within the multifunctional drug release membrane 2. The intelligent feedback system includes a micro-sensor 301 and a microcontroller unit 302, which are electrically connected. The micro-sensor 301 monitors environmental parameters around the catheter in real time, including elevated local skin temperature, and increases in inflammatory mediators such as IL-6, C-reactive protein (CRP), and procalcitonin (PCT). The micro-sensor 301 transmits the collected environmental parameters to the microcontroller unit 302, which adjusts the dynamic control module 4 based on the received data to achieve dynamic control of the release rate.

[0041] The dynamic control module 4 includes a microfluidic channel 401 and an EAP microvalve 402 located at the inlet of the microfluidic channel 401. The EAP microvalve 402 is electrically connected to the microcontroller unit 302 through a microvalve connecting line 403, thereby enabling the microcontroller unit 302 to directly control the release rate.

[0042] Meanwhile, the microcontroller unit 302 is wirelessly connected to the monitoring terminal 5 to wirelessly push the operating status of the internal jugular vein semi-permanent catheter to the external terminal so as to view real-time data and adjust the treatment plan.

[0043] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention and not to limit them. Although the present invention has been described in detail with reference to preferred embodiments, those skilled in the art should understand that modifications or equivalent substitutions can still be made to the technical solutions of the present invention, and these modifications or equivalent substitutions cannot cause the modified technical solutions to deviate from the spirit and scope of the technical solutions of the present invention.

Claims

1. A semi-permanent internal jugular vein catheter with an adaptive epidermal growth factor release mechanism, comprising a catheter body, characterized in that: The distal end of the catheter body is coated with a multifunctional drug release membrane, which contains an intelligent feedback system.

2. The internal jugular vein semi-permanent catheter with an adaptive epidermal growth factor release mechanism according to claim 1, characterized in that: The catheter body is made of medical-grade elastomer.

3. The internal jugular vein semi-permanent catheter with an adaptive epidermal growth factor release mechanism according to claim 1, characterized in that: The multifunctional drug delivery coating includes an epidermal growth factor coating and an antibacterial agent coating. The epidermal growth factor (EGF) and the antibacterial agent are coated onto the distal end of the catheter body using biocompatible polymers as carriers. The epidermal growth factor coating has epidermal growth factor distributed in increasing concentrations along the distal end of the catheter body towards the inner side, and the antibacterial agent coating has antibacterial agent distributed in increasing concentrations along the distal end of the catheter body towards the inner side.

4. The internal jugular vein semi-permanent catheter with an adaptive epidermal growth factor release mechanism according to claim 3, characterized in that: Biocompatible polymers include synthetic biocompatible polymers or natural biocompatible polymers; Synthetic biocompatible polymers include polylactic acid, polyglycolic acid, and polycaprolactone; Natural biocompatible polymers include collagen, chitosan, and cellulose.

5. The internal jugular vein semi-permanent catheter with an adaptive epidermal growth factor release mechanism according to claim 1, characterized in that: The intelligent feedback system includes micro-sensors and microcontroller units, which are electrically connected.

6. A semi-permanent internal jugular vein catheter with an adaptive epidermal growth factor release mechanism according to claim 5, characterized in that: The intelligent feedback system includes micro-sensors and microcontroller units, which are electrically connected.

7. A semi-permanent internal jugular vein catheter with an adaptive epidermal growth factor release mechanism according to claim 6, characterized in that: The miniature sensor monitors the environmental parameters around the catheter in real time and transmits the collected environmental parameters to the microcontroller unit. The microcontroller unit adjusts the dynamic control module according to the received data to achieve dynamic control of the release rate.

8. A semi-permanent internal jugular vein catheter with an adaptive epidermal growth factor release mechanism according to claim 5, characterized in that: The microcontroller unit is wirelessly connected to the monitoring terminal.

9. A semi-permanent internal jugular vein catheter with an adaptive epidermal growth factor release mechanism according to claim 7, characterized in that: The dynamic control module includes a microfluidic channel and an EAP microvalve located at the inlet of the microfluidic channel. The EAP microvalve is electrically connected to the microcontroller unit via a microvalve connection line.

Images